Estimating the long-term survival of unresectable stage III non-small cell lung cancer based on cure model analysis

The predictors of long-term survival and appropriate surrogate endpoints in unresectable stage III non-small cell lung cancer (NSCLC) treated with radiotherapy remain unclear, especially in the immune therapy era.